Daniel J. Kingsbury

Pediatric Rheumatology

501 N Graham St Ste 355 Office
Portland, OR 97227

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+-Year Results From a Multicenter, Open-Label Study.

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+-Year Results From a Multicenter, Open-Label Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 28, 2026

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study.

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 28, 2026

Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial.

Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial.

Journal: ACR open rheumatology

Published: March 11, 2025

Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.

Correction: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.

Journal: Arthritis research & therapy

Published: August 31, 2024

S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.

S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.

Journal: Arthritis research & therapy

Published: September 20, 2023

Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept.

Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept.

Journal: Arthritis care & research

Published: July 25, 2022

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.

Journal: Lancet (London, England)

Published: March 01, 2021

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.

Journal: Rheumatology (Oxford, England)

Published: August 04, 2020

New Medications Are Needed for Children With Juvenile Idiopathic Arthritis.

New Medications Are Needed for Children With Juvenile Idiopathic Arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 24, 2020

Poststreptococcal Reactive Arthritis: Diagnostic Challenges.

Poststreptococcal Reactive Arthritis: Diagnostic Challenges.

Journal: The Permanente journal

Published: January 14, 2020

Emergent high fatality lung disease in systemic juvenile arthritis.

Emergent high fatality lung disease in systemic juvenile arthritis.

Journal: Annals of the rheumatic diseases

Published: July 17, 2019

Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.

Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.

Journal: The Journal of clinical investigation

Published: April 02, 2019

Showing 1-12 of 23

Last Updated: 09/26/2026